Cargando…

Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer

Developing treatment strategies for triple-negative breast cancer (TNBC) has become an important clinical challenge. Currently, taxane-based chemotherapy is one of the standard treatments for TNBC. However, determining the key factor of taxane-resistance is urgently in need for clinical treatment fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chou, Ching-Wen, Huang, Yu-Min, Chang, Yu-Jia, Huang, Chien-Yu, Hung, Chin-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176163/ https://www.ncbi.nlm.nih.gov/pubmed/34104083 http://dx.doi.org/10.7150/ijms.59177

Ejemplares similares

The role of taxanes in triple-negative breast cancer: literature review
por: Mustacchi, Giorgio, et al.
Publicado: (2015)

The role of taxanes in triple-negative breast cancer: literature review [Corrigendum]
Publicado: (2015)

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
por: Schreiber, Anna R., et al.
Publicado: (2021)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021)

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population
por: Gómez-Miragaya, Jorge, et al.
Publicado: (2017)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer
por: Giordano, Antonio, et al.
Publicado: (2019)

Patterns and Predictors of First-Line Taxane Use in Patients with Metastatic Triple-Negative Breast Cancer in US Clinical Practice
por: O’Shaughnessy, Joyce, et al.
Publicado: (2021)

Role of Taxanes in Triple-Negative Breast Cancer: A Study From Tertiary Cancer Center in South India
por: Lakshmaiah, K.C., et al.
Publicado: (2017)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Efficacy and safety of taxanes combined with chemotherapy drugs in advanced triple negative breast cancer: A meta-analysis of 26 randomized controlled trials
por: Huang, Qionglian, et al.
Publicado: (2022)

Six novel immunoglobulin genes as biomarkers for better prognosis in triple-negative breast cancer by gene co-expression network analysis
por: Hsu, Huan-Ming, et al.
Publicado: (2019)

Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2018)

LncRNAs as new biomarkers to differentiate triple negative breast cancer from non-triple negative breast cancer
por: Lv, Mingming, et al.
Publicado: (2016)

Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides
por: Yu, Yung-Luen, et al.
Publicado: (2013)

Unraveling the Pivotal Network of Ultrasound and Somatic Mutations in Triple-Negative and Non-Triple-Negative Breast Cancer
por: Huang, Yunxia, et al.
Publicado: (2023)

Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing
por: Chang, Yao-Yin, et al.
Publicado: (2015)

Triple negative breast carcinoma is a prognostic factor in Taiwanese women
por: Lin, Che, et al.
Publicado: (2009)

Glucocorticoid Receptor Expression Predicts Good Outcome in response to Taxane-Free, Anthracycline-Based Therapy in Triple Negative Breast Cancer
por: Elkashif, Ahmed, et al.
Publicado: (2020)

Network-based approach to identify biomarkers predicting response and prognosis for HER2-negative breast cancer treatment with taxane-anthracycline neoadjuvant chemotherapy
por: Jiang, Cui, et al.
Publicado: (2019)

Disruption of the pentraxin 3/CD44 interaction as an efficient therapy for triple‐negative breast cancers
por: Hsiao, Yu‐Wei, et al.
Publicado: (2022)

Mechanisms of Taxane Resistance
por: Maloney, Sara M., et al.
Publicado: (2020)

CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance
por: Langebäck, Anette, et al.
Publicado: (2019)

Long Noncoding RNAs in Taxane Resistance of Breast Cancer
por: Chen, Hailong, et al.
Publicado: (2023)

Exploring Specific miRNA-mRNA Axes With Relationship to Taxanes-Resistance in Breast Cancer
por: Chen, Danni, et al.
Publicado: (2020)

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2016)

GBP5 Serves as a Potential Marker to Predict a Favorable Response in Triple-Negative Breast Cancer Patients Receiving a Taxane-Based Chemotherapy
por: Cheng, Shun-Wen, et al.
Publicado: (2021)

A systemic review of taxanes and their side effects in metastatic breast cancer
por: Lai, Jiun-I., et al.
Publicado: (2022)

Molecular Characteristics and Metastasis Predictor Genes of Triple-Negative Breast Cancer: A Clinical Study of Triple-Negative Breast Carcinomas
por: Kuo, Wen-Hung, et al.
Publicado: (2012)

A Novel IGLC2 Gene Linked With Prognosis of Triple-Negative Breast Cancer
por: Chang, Yu-Tien, et al.
Publicado: (2022)

Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors
por: Chen, Yun-Ju, et al.
Publicado: (2013)

Exploring specific prognostic biomarkers in triple-negative breast cancer
por: Bao, Chang, et al.
Publicado: (2019)

NAD(P)H:quinone oxidoreductase 1 determines radiosensitivity of triple negative breast cancer cells and is controlled by long non-coding RNA NEAT1
por: Lin, Li-Ching, et al.
Publicado: (2020)

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy
por: Bernier, Cynthia, et al.
Publicado: (2018)

Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy
por: Liao, Yuqian, et al.
Publicado: (2020)

The taxane-based chemotherapy triplet is superior to the doublet in one to nine node-positive but not node-negative triple-negative breast cancer: results from a retrospective analysis
por: Guo, Sanxing, et al.
Publicado: (2020)

Impact of Expression Levels of Platinum-uptake Transporters Copper Transporter 1 and Organic Cation Transporter 2 on Resistance to Anthracycline/Taxane-based Chemotherapy in Triple-negative Breast Cancer
por: Takeda, Risa, et al.
Publicado: (2015)

Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells
por: Tzeng, Yen-Dun Tony, et al.
Publicado: (2018)

A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status
por: Su, Ying-Wen, et al.
Publicado: (2018)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6jpm9bd3j532j9pi59b8pf1scg